Skip to main content

NovoCure Ltd

corporate_fare Company Profile

NovoCure Ltd

NVCR·NASDAQ·Industrial Applications And Services·CIK 0001645113

NovoCure Ltd is a global oncology company that utilizes a proprietary platform technology called Tumor Treating Fields ("TTFields"). This technology uses electric fields to physically kill cancer cells and is delivered via a medical device. The company's primary focus areas include increasing the commercial use of its TTFields therapy devices: Optune Gio®, Optune Lua®, and Optune Pax®. NovoCure also aims to secure regulatory approvals for TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to further clinical and product development programs designed to improve overall survival in aggressive cancers. Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") for adult patients with newly diagnosed glioblastoma ("GBM") when used with temozolomide, and for adult patients with GBM after confirmed recurrence following chemotherapy as a standalone treatment. Optune Gio also holds a CE certificate for GBM treatment in the European Union ("EU"), and has approval or local registration in the United Kingdom ("UK"), Japan, Canada, and other countries. Optune Lua is FDA-approved for adult patients with metastatic NSCLC, used concurrently with PD-1/PD-L1 inhibitors or docetaxel after progression on or following a platinum-based regimen. It also has a CE certificate for marketing in the EU for metastatic NSCLC under the same conditions. In Japan, Optune Lua received regulatory approval for adult patients with unresectable advanced/recurrent NSCLC, concurrent with PD-1/PD-L1 inhibitors after progression on or following a platinum-based regimen. Additionally, Optune Lua is FDA-approved under the Humanitarian Device Exemption ("HDE") for adult patients with malignant pleural mesothelioma or pleural mesothelioma ("MPM") when used with standard chemotherapies.

NovoCure Ltd (NASDAQ:NVCR) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 26 items for NVCR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • NovoCure Secures FDA Approval for Optune Pax in Pancreatic Cancer Amidst Mixed FY25 Financials and Clinical Setbacks
  • NovoCure Reports Q4/FY25 Results, Guides Towards 2026 Profitability Amidst CMO Resignation
  • CMS Reinstates NovoCure's Billing Privileges Retroactively, Reversing Prior Revocation
  • NovoCure Receives FDA Approval for Optune Pax in Locally Advanced Pancreatic Cancer
  • NovoCure's US Subsidiary Loses CMS Billing Privileges, Faces $13M Monthly Revenue Hit

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$655.35M
Net Income
-$136.23M
Diluted EPS
-$1.22
Op. Cash Flow
-$49.03M
Free Cash Flow
-$75.68M
Gross Profit
$488.47M
Operating Income
-$153.8M
Cash & Equivalents
$93.55M
Total Debt
$195.05M
Debt / Equity
0.57×
Net Margin
-20.8%
Shares Outstanding
112.49M sh
Source: 10-K · filed 2026-02-26 · accession 0001645113-26-000017
$10.71
52-week range · as of 2026-11-09 $9.82 – $21.45
Market cap
$1.25B
Volume
1.6M (0.9× avg)
3-mo avg 1.8M
Live data · 2026-11-22 07:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NVCR - Filings & News (Page 2)

NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $10.71 info
Change: -$3.77 (-26%) info
Market Cap: $1.252B info
NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $10.71 info
Change: -$3.77 (-26%) info
Market Cap: $1.252B info
NVCR
Feb 24, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.71
Real-time Price: $10.71 info
Change: -$2.00 (-16%) info
Market Cap: $1.252B info
NVCR
Feb 11, 2026, 5:24 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.50
Real-time Price: $10.71 info
Change: +$0.210 (+2%) info
Market Cap: $1.252B info
NVCR
Feb 05, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.51
Real-time Price: $10.71 info
Change: -$0.800 (-7%) info
Market Cap: $1.252B info
NVCR
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.35
Real-time Price: $10.71 info
Change: -$3.64 (-25%) info
Market Cap: $1.252B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets